Avanos Stockholders To Receive $25.00 Per Share in Cash

Avanos股东将每股获得25.00美元现金

ALPHARETTA, Ga. and NEW YORK

阿尔法利塔，乔治亚州和纽约

,

，

April 14, 2026

2026年4月14日

/PRNewswire/ -- Avanos Medical, Inc. (NYSE:

/PRNewswire/ -- Avanos Medical, Inc.（纽约证券交易所代码：

AVNS

先进车辆导航系统

), a leading medical technology company, today announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners ('AIP'), an operationally-oriented industrials investor, in an all-cash transaction that values Avanos at an enterprise value of approximately $1.272 billion..

），一家领先的医疗技术公司，今天宣布已与美国工业合作伙伴（“AIP”）的关联公司达成最终协议，将以全现金交易方式被收购，该交易对Avanos的企业估值约为12.72亿美元。

Under the terms of the agreement, Avanos stockholders will receive $25.00 per share in cash for each share of common stock they own. The per share purchase price represents a premium of approximately 72.1% to the Company's closing stock price on April 13, 2026, the last full trading day prior to the announcement of the transaction, and an 82.8% premium to the Company's 30-day volume-weighted average share price for the period ended April 13, 2026.

根据协议条款，Avanos 的股东每股普通股将获得 25.00 美元的现金。每股收购价格较公司于 2026 年 4 月 13 日（即交易宣布前的最后一个完整交易日）的收盘股价溢价约 72.1%，较公司截至 2026 年 4 月 13 日的 30 天成交量加权平均股价溢价 82.8%。

.

。

Gary Blackford, Avanos Board chair, said, 'Our agreement with AIP is a milestone for Avanos that reflects the strong momentum across the business. After careful consideration alongside our independent advisors, we are confident this agreement with AIP represents the right path forward for Avanos and its stockholders.

阿凡诺斯董事会主席加里·布莱克福德表示：“我们与AIP达成的协议是阿凡诺斯的一个重要里程碑，反映了公司业务的强劲势头。在与我们的独立顾问慎重考虑后，我们相信与AIP达成的这项协议将为阿凡诺斯及其股东带来正确的前进道路。”

The Board believes this transaction will maximize value for stockholders, create exciting new opportunities for employees, and best position Avanos for long‑term growth and success.'.

董事会认为，此次交易将使股东价值最大化，为员工创造令人兴奋的新机会，并使Avanos在长期内实现最佳的增长和成功定位。

David Pacitti, Avanos' chief executive officer, said, 'Over the past several years, we have taken deliberate steps to become a more focused medical technology organization, leaning into the categories where we can deliver the most clinical value. Partnering with AIP will better enable us to build on our progress, advance our innovation roadmap, and strengthen our competitive position with enhanced flexibility and resources.

大卫·帕奇蒂，阿瓦诺斯的首席执行官表示：“在过去的几年中，我们采取了深思熟虑的步骤，以成为一家更加专注的医疗技术组织，着力于我们能够提供最大临床价值的领域。与AIP合作将更好地使我们能够在已有进展的基础上继续发展，推动我们的创新路线图，并通过增强的灵活性和资源来巩固我们的竞争优势。”

AIP recognizes the strength of our talented employees and the role they serve in addressing today's most important healthcare needs. I look forward to working with AIP as the Avanos team begins a new chapter, marked by growth and compelling benefits for employees, patients, customers, and all our stakeholders.'.

AIP 认识到我们才华横溢的员工的力量，以及他们在满足当今最重要的医疗需求方面所发挥的作用。随着 Avanos 团队开启新的篇章，我期待与 AIP 合作，这将带来员工、患者、客户和所有利益相关者的成长和引人注目的利益。

Joel Rotroff, Partner at AIP, said, 'Avanos is a differentiated medical technology company with strong positions in attractive categories and a compelling platform for continued growth. We look forward to partnering with the Avanos team to build on the Company's momentum and support the next phase of innovation and commercial execution.'.

AIP合伙人乔尔·罗特罗夫表示：“Avanos是一家与众不同的医疗技术公司，在具有吸引力的领域拥有强大的地位，并且具备持续增长的令人信服的平台。我们期待与Avanos团队合作，推动公司的进一步发展，支持下一阶段的创新和商业执行。”

Sunny Li, Partner at AIP, added, 'We have been impressed by the work the management team has done to position Avanos for growth, as well as by the strength of the Company's people and products. We believe this partnership, together with AIP's deep operational capabilities, will help advance management's vision and position Avanos for long-term success.'.

AIP合伙人Sunny Li补充道：“管理层为Avanos的业务增长所做的工作、公司员工和产品的实力让我们印象深刻。我们相信，通过与AIP深入的运营能力相结合，这一合作关系将有助于推动管理层的愿景，为Avanos的长期成功奠定基础。”

Transaction Details

交易明细

The acquisition was unanimously approved by Avanos' Board of Directors and is expected to close in the second half of 2026, subject to customary conditions, including approval by Avanos stockholders and expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as well as the receipt of other regulatory approvals.

该收购已获得Avanos董事会的一致批准，预计将于2026年下半年完成，但需满足惯例条件，包括Avanos股东的批准、《1976年哈特-斯科特-罗迪诺反托拉斯改进法》适用的等待期届满，以及其他监管机构的批准。

The transaction is not subject to a financing condition..

该交易不受融资条件的限制。

Upon completion of the transaction, Avanos will become a private company and Avanos common stock will no longer be listed on the New York Stock Exchange. Avanos will remain headquartered in Alpharetta, Georgia.

交易完成后，Avanos将成为一家私人公司，其普通股将不再在纽约证券交易所上市。Avanos总部仍将设在乔治亚州阿尔法利塔。

As a result of the transaction, Avanos has postponed its 2026 Annual Meeting of Stockholders, which was previously scheduled for April 21, 2026, at 9:00 a.m. ET.

由于该交易，Avanos 已经推迟了原定于 2026 年 4 月 21 日东部时间上午 9:00 举行的 2026 年股东年会。

Advisors

顾问

J.P. Morgan Securities LLC is serving as lead financial advisor and Alston & Bird, LLP, is serving as legal counsel to Avanos. UBS Investment Bank also served as a financial advisor to Avanos. Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor to Avanos.

摩根大通证券有限责任公司担任首席财务顾问，阿尔斯通与伯德律师事务所（Alston & Bird, LLP）担任Avanos的法律顾问。瑞银投资银行也担任了Avanos的财务顾问。Joele Frank, Wilkinson Brimmer Katcher担任Avanos的战略沟通顾问。

Sidley Austin LLP is serving as legal counsel to AIP and Baker Botts LLP is serving as regulatory counsel to AIP.

盛德国际律师事务所担任AIP的法律顾问，贝克博茨律师事务所担任AIP的监管顾问。

About Avanos Medical, Inc.

关于Avanos医疗公司

Avanos Medical, Inc. (NYSE:

Avanos医疗公司（纽约证券交易所：

AVNS

高级虚拟网络服务

) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to what matters. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery.

）是一家医疗技术公司，专注于提供临床优越的医疗器械解决方案，帮助患者重拾生活重点。公司总部位于乔治亚州阿尔法利塔，我们致力于满足当今一些最重要的医疗需求，包括为患者提供从医院到家庭的关键营养生命线，以及减少阿片类药物的使用，同时帮助患者从手术过渡到康复。

We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook..

我们在全球范围内开发、生产和销售我们的知名品牌，并在我们产品组合的多个类别中占据领先的市场地位。欲了解更多信息，请访问avanos.com，并在X（@AvanosMedical）、领英和脸书上关注Avanos Medical。

About American Industrial Partners

关于美国工业合作伙伴

American Industrial Partners is an operationally oriented industrials investor with approximately $17.5 billion in assets under management. AIP seeks to achieve differentiated returns by investing in quality engineered products businesses with strong management teams and working with those teams to implement transformative Operating Agendas to build long-term value.

美国工业合作伙伴是一家以运营为导向的工业投资者，管理的资产约为175亿美元。AIP通过投资拥有强大管理团队的优质工程产品企业，与这些团队合作实施变革性的运营计划，以实现差异化回报并创造长期价值。

The AIP team has deep roots in the industrial economy and has actively invested across three economic cycles. AIP has completed over 145 platform and add-on acquisitions and invests in all forms of corporate divestitures, management buyouts, recapitalizations, and going-private transactions of established businesses with sales greater than $500 million.

AIP团队在工业经济领域有着深厚的根基，并积极投资于三个经济周期。AIP已完成超过145项平台及附加收购，投资于各种形式的企业剥离、管理层收购、资本重组以及年销售额超过5亿美元的成熟企业的私有化交易。

Current AIP portfolio companies generate aggregate annual revenues of $24.7 billion and employ approximately 54,000 employees as of December 31, 2025..

截至2025年12月31日，当前AIP投资组合公司产生的总年度收入为247亿美元，雇员约54,000人。

Forward-Looking Statements

前瞻性声明

This document contains information that includes or is based on 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as 'believe,' 'will,' or 'positioned,' and similar expressions.

本文件包含的信息包括或基于1995年《私人证券诉讼改革法案》中定义的“前瞻性陈述”。前瞻性陈述包括所有不单纯与历史或当前事实相关的陈述，通常可以通过使用诸如“相信”、“将”或“定位”等词语以及类似表述来识别。

These 'forward-looking statements' include statements about the acquisition and related transactions, including the timing of the completion of the acquisition and the potential benefits of the acquisition, which reflect the current analysis of existing information and are subject to various risks and uncertainties.

这些“前瞻性声明”包括关于收购及相关交易的声明，包括收购完成的时间和收购的潜在好处，这些声明反映了对现有信息的当前分析，并受各种风险和不确定性的影响。

As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, Avanos' actual results may differ materially from its expectations or projections. The following factors, among others, could cause actual plans and results to differ materially from those described in forward-looking statements: (i) uncertainties as to the timing of the acquisition, (ii) the possibility that competing acquisition proposals will be made; (iii) the possibility that Avanos will terminate the merger agreement to enter into an alternative transaction; (iv) the possibility that various closing conditions for the transactions contemplated by the merger agreement may not be satisfied or waived; (v) the risk that the merger agreement may be terminated in circumstances requiring Avanos to pay a termination fee; (vi) the potential impact of the announcement or consummation of the proposed transactions on Avanos' relationships, including with employees, suppliers and customers; and (vii) the other factors and financial, operational and legal risks or .

因此，在依赖前瞻性陈述时必须谨慎。由于已知和未知的风险，Avanos的实际结果可能与其预期或预测有重大差异。以下因素（包括但不限于）可能导致实际计划和结果与前瞻性陈述中描述的内容有重大差异：(i) 关于收购时间的不确定性，(ii) 可能会出现竞争性的收购提议；(iii) Avanos可能终止合并协议以进入替代交易；(iv) 合并协议中设想的交易可能无法满足或豁免各种交割条件；(v) 在需要Avanos支付终止费的情况下合并协议可能被终止的风险；(vi) 公布或完成拟议交易可能对Avanos的关系产生的潜在影响，包括与员工、供应商和客户的关系；以及(vii) 其他因素及财务、运营和法律风险或不确定性。

Important Additional Information

重要附加信息

In connection with the proposed transactions, Avanos intends to file with the SEC a proxy statement on Schedule 14A (the 'Proxy Statement'). The definitive Proxy Statement (if and when available) will be mailed to stockholders of Avanos. Avanos may also file with or furnish to the SEC other relevant documents regarding the proposed transactions.

与此相关的拟议交易，Avanos 打算向美国证券交易委员会提交一份按照14A表编制的委托书声明（“委托书声明”）。最终的委托书声明（如果有的话，在可用时）将邮寄给Avanos的股东。Avanos 还可能向美国证券交易委员会提交或提供与拟议交易相关的其他重要文件。

This communication is not a substitute for the Proxy Statement or any other document that Avanos may mail to its stockholders in connection with the proposed transactions..

本通讯并非代理声明或 Avanos 可能就拟议交易向其股东邮寄的任何其他文件的替代品。

INVESTORS AND STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ACCOMPANYING PROXY CARD AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION..

强烈鼓励投资者和股东在代理声明、任何修订或补充文件、随附的代理卡以及向美国证券交易委员会提交的其他文件可用时，仔细并完整地阅读这些文件，因为它们将包含重要信息。

Avanos Medical, Inc., its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Avanos' stockholders in connection with proposed transactions under the rules of the SEC. Detailed information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed transactions when they become available.

Avanos Medical, Inc. 及其董事、高级管理人员和其他管理层成员及员工可能被视为根据美国证券交易委员会 (SEC) 规则，在与拟议交易相关的 Avanos 股东委托书征集活动中成为参与者。有关潜在参与者的身份及其通过持股或其他方式直接或间接利益的详细信息，将在与拟议交易相关的委托书声明及其他提交给 SEC 的材料中列出，这些文件将在可用时提供。

Information regarding the direct and indirect beneficial ownership of the Company's directors and executive officers in its securities is included in their SEC filings on Forms 3, 4 and 5, and additional information can also be found in the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC.

公司董事和高级管理人员在其证券中的直接和间接实益所有权的相关信息包含在他们向美国证券交易委员会（SEC）提交的表格3、4和5中，更多信息也可以在公司向SEC提交的年度报告表格10-K及其季度报告表格10-Q中找到。

Stockholders will be able to obtain any proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC for no charge at the SEC's website at .

股东将能够免费在SEC的网站上获取任何代理声明、代理声明的任何修订或补充文件以及公司向SEC提交的其他文件。

www.sec.gov

www.sec.gov

. Copies will also be available at no charge at the Investors section of Avanos' website at

. 投资者可以在Avanos官网的投资者栏目免费获取副本。

www.avanos.com

www.avanos.com

.

。

SOURCE Avanos Medical

来源：Avanos Medical

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示